Identification of a Novel PPAR Signature for Predicting Prognosis, Immune Microenvironment, and Chemotherapy Response in Bladder Cancer

Figure 5

Validation of the PPAR signature in the GEO dataset. (a–e) Kaplan-Meier curve showed that low-risk patients had better survival compared with the high-risk patients. The distribution of overall survival between the high-risk group and the low-risk group. The distribution of PPARscore between the high-risk group and the low-risk group ((a) GSE13507; (e) GSE32894); (b–f) time-independent receiver operating characteristic (ROC) analysis for evaluating the predictive performance of PPARscore ((b) GSE13507; (f) GSE32894); (c–g) heatmap showed the expression patterns of 4 genes between the high- and low-risk groups ((c) GSE13507; (g) GSE32894). The blue box represented the GSE13507 dataset; the red box represented the GSE32894 dataset.

(a)

(b)

(c)

(d)

(e)

(f)